Ceftobiprole medocaril is under clinical development by Basilea Pharmaceutica and currently in Phase III for Skin And Skin Structure Infections (SSSI). According to GlobalData, Phase III drugs for Skin And Skin Structure Infections (SSSI) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ceftobiprole medocaril’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ceftobiprole medocaril overview
Ceftobiprole medocaril (Zeftera/Zevtera/Mabelio) a broad-spectrum cephalosporin antibiotic. It is formulated as powder for solution for intravenous administration. Zevtera is indicated for the treatment of the following infections in adults : Hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), Community-acquired pneumonia (CAP). Zeftera is indicated for the treatment of the following infections when caused by complicated skin and skin structure infections (cSSSI), including non-limb threatening diabetic foot infections without concomitant osteomyelitis caused by: Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus aureus (including methicillin-resistant isolates), and Streptococcus pyogenes.
It is also under development for the treatment of bacterial endocarditis, skin and skin structure infections (SSSI) caused by bacteria, sepsis and Staphylococcus aureus bacteremia. It was under development for the treatment of diabetic foot infection (DFI), methicillin-resistant Staphylococcus Aureus (MRSA) infections, hospital acquired pneumonia (HAP), community acquired pneumonia and pneumonia.
Basilea Pharmaceutica overview
Basilea Pharmaceutica (Basilea) is a biopharmaceutical company. It develops and markets antibiotics, antifungals and oncology drugs. The company’s pipeline products include fosmanogepix, which treats candidemia and invasive candidiasis; Isavuconazole for invasive aspergillosis and mucormycosis; BAL2062, which targets invasive aspergillosis; ceftobiprole, which treats bacterial pneumonia; tonabacase for several staphylococcal infections. It markets its products under Cresemba and Zevtera. The company also operates in Russia, the US, China, Germany, Switzerland and Canada. Basilea is headquartered in Basel, Zurich, Switzerland.
For a complete picture of Ceftobiprole medocaril’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
